Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Therapeutic Devices

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$58.2M

Valuation

$0000 

About PercuSurge

PercuSurge pioneered a new market segment in interventional cardiology products with a series of balloon catheters designed to trap and remove the potentially harmful debris that breaks loose during balloon angioplasty and stent placement procedures.

PercuSurge Headquarter Location

Sunnyvale, California, 55432,

United States

Latest PercuSurge News

Medtronic to acquire PercuSurge for $225 million

Jul 21, 2017

In a move that will further enhance its interventional vascular product offerings, Medtronic Inc. (Minneapolis) today announced that it will acquire Sunnyvale, CA-based PercuSurge Inc. The merger agreement calls for an exchange of stock valued at approximately $225 million. Further financial details were not disclosed. PercuSurge will join the Medtronic Vascular organization, which is headquartered in Santa Rosa, CA. "We are excited to be joined by this innovative company, whose embolic protection device is the 'best in class' solution for reducing clinical complications associated with embolic debris released during interventional procedures," said Andy Rasdal, president of Medtronic Vascular. "We believe that our technology and excellent clinical results, combined with Medtronic AVE's worldwide operational and field infrastructure will result in an extremely rapid adoption of our technology to treat the nearly 200,000 diseased saphenous vein bypass grafts that could be treated each year," said Peter Rule, president, CEO and chairman of PercuSurge. The PercuSurge GuardWire Plus Temporary Occlusion and Aspiration system is designed to allow cardiologists and other interventional specialists to capture embolic debris that might otherwise block downstream vessels and branches during interventional procedures and damage the heart. It consists of a balloon-tipped guidewire, which is inflated briefly to occlude blood flow and capture any material dislodged from the wall of the vessel during placement of a stent upstream. Captured material is then withdrawn by using the PercuSurge Export aspiration catheter before the balloon of the GuardWire Plus is deflated and blood flow restored. The device has been used in over 5,000 procedures since its release in Europe during 1999 and was the first distal protection product to be commercialized there. The product's first targeted indication is for the treatment of degenerated saphenous vein grafts that show signs of disease following heart bypass surgery. The GuardWire Plus is an investigational device in the United States, and clinical trials are already underway. Edited by Ursula Jones

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.